CRISPR-Cas9基因编辑技术在病毒感染疾病治疗中的应用

doi:10.16288/j.yczz.14-460

遗传 ›› 2015, Vol. 37 ›› Issue (5): 412-418.doi: 10.16288/j.yczz.14-460

CRISPR-Cas9基因编辑技术在病毒感染疾病治疗中的应用

殷利眷,胡斯奇,郭斐

中国医学科学院/北京协和医学院病原生物学研究所,卫生部病原系统生物学重点实验室,北京 100730

收稿日期:2014-12-24 出版日期:2015-05-20 发布日期:2015-05-20
通讯作者: 郭斐,博士,研究员,研究方向：分子病毒学。E-mail: guoafei@ipbcams.ac.cn
作者简介:殷利眷,硕士研究生,专业方向：病毒与宿主限制因子相互作用。E-mail: yljzhx@sina.com
基金资助:
国家自然科学基金项目(编号：81371808)资助

The application of CRISPR-Cas9 gene editing technology in viral infection diseases

Lijuan Yin, Siqi Hu, Fei Guo

MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Received:2014-12-24 Online:2015-05-20 Published:2015-05-20

摘要/Abstract

摘要： CRISPR-Cas9基因编辑技术是基于细菌或古细菌CRISPR介导的获得性免疫系统衍生而来,由一段RNA通过碱基互补配对识别DNA,指导Cas9核酸酶切割识别的双链DNA,诱发同源重组或非同源末端链接,进而实现在目的DNA上进行编辑。病毒通过特异的受体侵染细胞,其基因组在细胞内发生复制、转录、翻译等过程完成其生活周期,某些DNA病毒或逆转录病毒基因组会整合到宿主基因组中。基因治疗是病毒感染疾病治疗的新趋势。因此,基因编辑技术在持续感染的病毒或潜伏感染病毒疾病治疗中具有重大的潜在意义。文章主要从CRISPR-Cas9作用机制以及在病毒感染疾病治疗中的应用等方面进行了综述。

关键词: CRISPR, 同源重组, 非同源末端链接, 基因编辑, 病毒

Abstract: The RNA-guided Cas9 nuclease from microbial clustered regularly interspaced short palindromic repeats (CRISPR) adaptive immune system has been used to facilitate efficient genome engineering in eukaryotic cells. The specific targeted genome is recognized and cut by gRNA-directed CRISPR/Cas9 complex, specifically by the endonuclease Cas9. The targeted gene locus could be repaired either by homology-directed repair or nonhomologous end joining, thus achieving a desired editing outcome. Viruses infect cells through specific receptors, and then the viral genome is transcribed, replicated and translated to complete its life cycle. As a result, some DNA virus and retrovirus genomes are integrated into the cellular genome. Gene therapy is a new trend to treat viral infected diseases. Given its designable sequence-specific editing of the targeted genome, CRISPR/Cas9 has tremendous potential in treating persistent and latent viral infections. In this review, we summarize the mechanism and progresses of CRISPR/Cas9, and also highlight its therapeutic application in infectious diseases.

Key words: CRISPR, homology-directed repair, nonhomologous end joining, gene editing, virus

殷利眷,胡斯奇,郭斐. CRISPR-Cas9基因编辑技术在病毒感染疾病治疗中的应用[J]. 遗传, 2015, 37(5): 412-418.

Lijuan Yin, Siqi Hu, Fei Guo. The application of CRISPR-Cas9 gene editing technology in viral infection diseases[J]. HEREDITAS(Beijing), 2015, 37(5): 412-418.

参考文献

[1] Capecchi MR. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat Rev Genet , 2005, 6(6): 507-512.
[2] Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet , 2010, 11(9): 636-646.
[3] Miller JC, Tan SY, Qiao GJ, Barlow KA, Wang JB, Xia DF, Meng XD, Paschon DE, Leung E, Hindley SJ, Dulay GP, Hua KL, Ankoudinova I, Cost GJ, Urnov FD, Zhang HS, Holmes MC, Zhang L, Gregory PD, Rebar EJ. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol , 2011, 29(2): 143-148.
[4] Wyman C, Kanaar R. DNA double-strand break repair: all's well that ends well. Annu Rev Genet , 2006, 40: 363-383.
[5] Cong L, Ran FA, Cox D, Lin SL, Barretto R, Habib N, Hsu PD, Wu XB, Jiang WY, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science , 2013, 339(6121): 819-823.
[6] Sorek R, Kunin V, Hugenholtz P. CRISPR—a widespread system that provides acquired resistance against phages in bacteria and archaea. Nat Rev Microbiol , 2008, 6(3): 181-186.
[7] Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli , and identification of the gene product. J Bacteriol , 1987, 169(12): 5429-5433.
[8] Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology , 2005, 151(8): 2551-2561.
[9] Mojica FJM, Díez-Villaseñor C, García-Martínez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol , 2005, 60(2): 174-182.
[10] Pourcel C, Salvignol G, Vergnaud G. CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology , 2005, 151(3): 653-663.
[11] Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science , 2007, 315(5819): 1709-1712.
[12] Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao YJ, Pirzada ZA, Eckert MR, Vogel J, Charpentier E. CRISPR RNA maturation by trans -encoded small RNA and host factor RNase III. Nature , 2011, 471(7340): 602-607.
[13] Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science , 2012, 337(6096): 816-821.
[14] Garneau JE, Dupuis MÈ, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath P, Magadán AH, Moineau S. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature , 2010, 468(7320): 67-71.
[15] Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA , 2012, 109(39): E2579-E2586.
[16] Mali P, Yang LH, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science , 2013, 339(6121): 823-826.
[17] Jinek M, East A, Cheng A, Lin S, Ma EB, Doudna J. RNA-programmed genome editing in human cells. Elife , 2013, 2: e00471.
[18] Cho SW, Kim S, Kim JM, Kim JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol , 2013, 31(3): 230-232.
[19] Ota S, Kawahara A. Zebrafish: a model vertebrate suitable for the analysis of human genetic disorders. Congenit Anom , 2014, 54(1): 8-11.
[20] Xue W, Chen SD, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, Cai WX, Yang GL, Bronson R, Crowley DG, Zhang F, Anderson DG, Sharp PA, Jacks T. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature , 2014, 514(7522): 380-384.
[21] Holt N, Wang JB, Kim K, Friedman G, Wang XC, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo . Nat Biotechnol , 2010, 28(8): 839-847.
[22] Perez EE, Wang JB, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll RG, Orange JS, Urnov FD, Rebar EJ, Ando D, Gregory PD, Riley JL, Holmes MC, June CH. Establishment of HIV-1 resistance in CD4 + T cells by genome editing using zinc-finger nucleases. Nat Biotechnol , 2008, 26(7): 808-816.
[23] Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med , 2014, 370(10): 901-910.
[24] Ye L, Wang JM, Beyer AI, Teque F, Cradick TJ, Qi ZX, Chang JC, Bao G, Muench MO, Yu JW, Levy JA, Kan YW. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA , 2014, 111(26): 9591-9596.
[25] Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep , 2013, 3: 2510.
[26] Hu WH, Kaminski R, Yang F, Zhang YG, Cosentino L, Li F, Luo B, Alvarez-Carbonell D, Garcia-Mesa Y, Karn J, Mo XM, Khalilli K. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA , 2014, 111(31): 11461-11466.
[27] Wang JB, Quake SR. RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci USA , 2014, 111(36): 13157-13162.
[28] Bi YW, Sun L, Gao DD, Ding C, Li ZH, Li YD, Cun W, Li QH. High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. PLoS Pathog , 2014, 10(5): e1004090.
[29] De Villiers EM. Heterogeneity of the human papillomavirus group. J Virol , 1989, 63(11): 4898-4903.
[30] Zhen S, Hua L, Takahashi Y, Narita S, Liu YH, Li Y. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochem Biophys Res Commun , 2014, 450(4): 1422-1426.
[31] Kennedy EM, Kornepati AVR, Goldstein M, Bogerd HP, Poling BC, Whisnant AW, Kastan MB, Cullen BR. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J Virol , 2014, 88(20): 11965- 11972.
[32] Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, Lin YY, Wang HY, Wang CC, Shen YC, Wu FY, Kao JH, Chen DS, Chen PJ. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo . Mol Ther Nucleic Acids , 2014, 3(8): e186.
[33] Fu YF, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol , 2013, 31(9): 822-826.
[34] Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li YQ, Fine EJ, Wu XB, Shalem O, Cradick TJ, Marraffini LA, Bao G, Zhang F. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol , 2013, 31(9): 827-832.
[35] Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konemann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y, Zhang F. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell , 2013, 154(6): 1380-1389.
[36] Shen B, Zhang WS, Zhang J, Zhou JK, Wang JY, Chen L, Wang L, Hodgkins A, Iyer V, Huang XX, Skarnes WC. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods , 2014, 11(4): 399-402.
[37] Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon D, Goodwin MJ, Aryee MJ, Joung JK. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol , 2014, 32(6): 569-576.
[38] Maggio I, Holkers M, Liu J, Janssen JM, Chen XY, Goncalves MA. Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells. Sci Rep , 2014, 4: 5105.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

CRISPR-Cas9基因编辑技术在病毒感染疾病治疗中的应用

The application of CRISPR-Cas9 gene editing technology in viral infection diseases

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	宗媛,高彩霞. 碱基编辑系统研究进展[J]. 遗传, 2019, 41(9): 777-800.
[2]	杨新萍,于媛,许操. 重新设计与快速驯化创造新型作物[J]. 遗传, 2019, 41(9): 827-835.
[3]	卢涣滋,王迪侃,王智. HPV阳性口咽癌患者预后与T细胞浸润和新抗原负荷相关性分析[J]. 遗传, 2019, 41(8): 725-735.
[4]	张倩倩,商璇,林宛颖,徐湘民. 影响β-地中海贫血表型的遗传修饰作用[J]. 遗传, 2019, 41(8): 669-676.
[5]	牛煦然,尹树明,陈曦,邵婷婷,李大力. 基因编辑技术及其在疾病治疗中的研究进展[J]. 遗传, 2019, 41(7): 582-598.
[6]	黄羽,胡斯奇,郭斐. 应激颗粒与病毒的相互制约[J]. 遗传, 2019, 41(6): 494-508.
[7]	郑晓飞,黄海燕,吴强. 染色质架构蛋白CTCF调控UGT1基因簇的表达[J]. 遗传, 2019, 41(6): 509-523.
[8]	王珏, 黄娟, 许蕊. 利用CRISPR/Cas9和piggyBac实现果蝇基因组无缝编辑[J]. 遗传, 2019, 41(5): 422-429.
[9]	薛鹏, 蒋涛, 沈兴家. m ⁶A修饰及其对病毒复制过程调控研究进展[J]. 遗传, 2019, 41(5): 404-412.
[10]	欧浩,李国玲,王豪强,黄广燕,蔡更元,李紫聪,吴珍芳,张献伟. MEK抑制剂PD0325901显著提高猪胎儿成纤维细胞ssODN介导的HDR效率[J]. 遗传, 2019, 41(4): 327-336.
[11]	张楷, 刘蔚, 刘小凤, 陈瑶生, 刘小红, 何祖勇. 利用CRISPR/Cas9系统构建人HPRT1基因定点突变细胞株[J]. 遗传, 2019, 41(10): 939-949.
[12]	李帆, 余蓉培, 孙丹, 王继华, 李绅崇, 阮继伟, 单芹丽, 陆平利, 汪国鲜. 抑制植物减数分裂重组的分子机理[J]. 遗传, 2019, 41(1): 52-65.
[13]	刘恒, 李东明, 朱兰玉, 赖乐锦, 闫婉云, 陆玉双, 韦伊, 黄月琪, 方媚, 苏元港, 杨芳, 舒伟. 利用CRISPR/Cas9敲除人源细胞系中LMNA基因的研究[J]. 遗传, 2019, 41(1): 66-75.
[14]	任云晓, 肖茹丹, 娄晓敏, 方向东. 基因编辑技术及其在基因治疗中的应用[J]. 遗传, 2019, 41(1): 18-27.
[15]	全绒, 李国玲, 莫健新, 钟翠丽, 李紫聪, 顾婷, 郑恩琴, 刘德武, 蔡更元, 吴珍芳, 张献伟. RNA干扰猪NHEJ通路修复因子对HR效率的影响[J]. 遗传, 2018, 40(9): 749-757.